×

Risperidone or paliperidone implant formulation

  • US 10,335,366 B2
  • Filed: 11/26/2014
  • Issued: 07/02/2019
  • Est. Priority Date: 05/31/2010
  • Status: Active Grant
First Claim
Patent Images

1. An injectable composition consisting ofabout 13% wt of drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination;

  • anda polymeric solution consisting of DMSO and biocompatible poly(lactide-co-glycolide) (PLGA) copolymer having a monomer ratio of lactic acid to glycolic acid of about 50;

    50 and an inherent viscosity in the range of 0.25-0.30 dl/g measured by gel permeation chromatography in tetrahydrofuran at 30°

    C. using a flow rate of 1 ml/min;

    whereinthe mass ratio of polymeric solution to drug is about 6.5;

    1 to about 7;

    1; and

    the mass ratio of DMSO to drug is about 4;

    1 to about 5;

    1.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×